Please use this identifier to cite or link to this item:
|Title:||Soy Milk Versus Simvastatin For Preventing Atherosclerosis And Left Ventricle Remodeling In Ldl Receptor Knockout Mice|
A. P.; Almeida
T. I. R.; Almeida
M. R.; Soares
E. A.; Fernandes
G. J. M.; Magalhaes
S. F.; Barauna
V. G.; Garcia
J. A. D.
|Abstract:||Functional food intake has been highlighted as a strategy for the prevention of cardiovascular diseases by reducing risk factors. In this study, we compared the effects of oral treatment with soy milk and simvastatin on dyslipidemia, left ventricle remodeling and atherosclerotic lesion of LDL receptor knockout mice (LDLr-/-) fed a hyperlipidic diet. Forty 3-month old male LDLr-/-mice were distributed into four groups: control group (C), in which animals received standard diet; HL group, in which animals were fed a hyperlipidic diet; HL+ SM or HL+ S groups, in which animals were submitted to a hyperlipidic diet plus soy milk or simvastatin, respectively. After 60 days, both soy milk and simvastatin treatment prevented dyslipidemia, atherosclerotic lesion progression and left ventricle hypertrophy in LDLr-/-mice. These beneficial effects of soy milk and simvastatin were associated with reduced oxidative stress and inflammatory state in the heart and aorta caused by the hyperlipidic diet. Treatment with soy milk was more effective in preventing HDLc reduction and triacylglycerol and VLDLc increase. On the other hand, simvastatin was more effective in preventing an increase in total cholesterol, LDLc and superoxide production in aorta, as well as CD40L both in aorta and left ventricle of LDLr-/-. In conclusion, our results suggest a cardioprotective effect of soy milk in LDLr-/-mice comparable to the well-known effects of simvastatin.|
|Editor:||Assoc Bras Divulg Cientifica|
|Citation:||Brazilian Journal Of Medical And Biological Research. Assoc Bras Divulg Cientifica, v. 50, p. , 2017.|
|Appears in Collections:||Unicamp - Artigos e Outros Documentos|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.